ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies
Author:
Open Access
- 29 October 2014
- journal article
- Published by Rambam Health Corporation in Rambam Maimonides Medical Journal
- Vol. 5 (4) , e0026
Abstract
Thrombotic microangiopathies (TMAs) comprise a group of distinct disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis. For many years distinction between these TMAs, especially between thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), remained purely clinical and hard to make. Recent discoveries shed light on different pathogenesis of TTP and HUS. Ultra-large von Willebrand factor (UL-VWF) platelet thrombi, resulting from the deficiency of cleavage protease which is now known as ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), were found to cause TTP pathology, while Shiga toxins or abnormalities in regulation of the complement system cause microangiopathy and thrombosis in HUS. TMAs may appear in various conditions such as pregnancy, inflammation, malignancy, or exposure to drugs. These conditions might cause acquired TTP, HUS, or other TMAs, or might be a trigger in individuals with genetic predisposition to ADAMTS-13 or complement factor H deficiency. Differentiation between these TMAs is highly important for urgent initiation of appropriate therapy. Measurement of ADAMTS-13 activity and anti-ADAMTS-13 antibody levels may advance this differentiation resulting in accurate diagnosis. Additionally, assessment of ADAMTS-13 levels can be a tool for monitoring treatment efficacy and relapse risk, allowing consideration of therapy addition or change. In the past few years, great improvements in ADAMTS-13 assays have been made, and tests with increased sensitivity, specificity, reproducibility, and shorter turnaround time are now available. These new assays enable ADAMTS-13 measurement in routine clinical diagnostic laboratories, which may ultimately result in improvement of TMA management.Keywords
This publication has 85 references indexed in Scilit:
- Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpuraBlood, 2012
- N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and miceJournal of Clinical Investigation, 2011
- Methodologies and Clinical Utility of ADAMTS-13 Activity TestingSeminars in Thrombosis and Hemostasis, 2010
- ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism?Annals of Hematology, 2009
- Molecular mechanisms of preeclampsiaMicrovascular Research, 2008
- Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic PurpuraJACC, 2007
- The molecular biology of thrombotic microangiopathyKidney International, 2006
- Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnanciesEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2003
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982
- Congenital Deficiency of a Factor in Normal Plasma That Reverses Microangiopathic Hemolysis and ThrombocytopeniaNew England Journal of Medicine, 1978